Skip To Main Content
Linda Barbieri on Muck Rack

Linda Barbieri

As seen in: MDPI, ACS Publications, Royal Society of Chemistry, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Linda

Contact Linda, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer

|
By Linda Barbieri, Lucia Salvioni, Andrea Banfi, Stefania Garbujo
| ACS Publications
Introduction Click to copy section linkSection link copied! Breast cancer (BC) is the most frequent malignancy in women worldwide and remains the second most common cause of cancer death among females. BC represents about 12% of all new cancer cases each year and 25% of all cancers in women. Early stage noninvasive or locally invasive BC can be cured in almost 70–80% of patients.
Open in Who Shared Issue with article?

Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer

|
By Linda Barbieri, Lucia Salvioni, Andrea Banfi, Stefania Garbujo
| dx.doi.org
Introduction Click to copy section linkSection link copied! Breast cancer (BC) is the most frequent malignancy in women worldwide and remains the second most common cause of cancer death among females. BC represents about 12% of all new cancer cases each year and 25% of all cancers in women. Early stage noninvasive or locally invasive BC can be cured in almost 70–80% of patients.
Open in Who Shared Issue with article?

Dual-targeting strategy to repurpose Cetuximab with HFn nanoconjugates for immunotherapy of triple-negative breast cancer

|
By Linda Barbieri, Lucia Salvioni, Andrea Banfi, Stefania Garbujo
| BioRxiv
Abstract Triple-negative breast cancer (TNBC) is a highly aggressive and treatment-resistant malignancy, characterized by the lack of targeted therapies and poor clinical outcomes. Here, we present a dual-targeting strategy combining the anti-EGFR monoclonal antibody Cetuximab (CTX) with H-ferritin (HFn), a nanoparticle targeting transferrin receptor 1 (TfR1), for potential immunotherapy in CTX-resistant tumors.
Open in Who Shared Issue with article?
See all 6 articles